Professional Documents
Culture Documents
New Insights Into Functional Mapping in Cerebral Tumor Surgery Hugues Duffau 2009
New Insights Into Functional Mapping in Cerebral Tumor Surgery Hugues Duffau 2009
No part of this digital document may be reproduced, stored in a retrieval system or transmitted in any form or
by any means. The publisher has taken reasonable care in the preparation of this digital document, but makes no
expressed or implied warranty of any kind and assumes no responsibility for any errors or omissions. No
liability is assumed for incidental or consequential damages in connection with or arising out of information
contained herein. This digital document is sold with the clear understanding that the publisher is not engaged in
rendering legal, medical or any other professional services.
NEW INSIGHTS INTO FUNCTIONAL
MAPPING IN CEREBRAL TUMOR
SURGERY
HUGUES DUFFAU
All rights reserved. No part of this book may be reproduced, stored in a retrieval system or
transmitted in any form or by any means: electronic, electrostatic, magnetic, tape, mechanical
photocopying, recording or otherwise without the written permission of the Publisher.
For permission to use material from this book please contact us:
Telephone 631-231-7269; Fax 631-231-8175
Web Site: http://www.novapublishers.com
Independent verification should be sought for any data, advice or recommendations contained
in this book. In addition, no responsibility is assumed by the publisher for any injury and/or
damage to persons or property arising from any methods, products, instructions, ideas or
otherwise contained in this publication.
This publication is designed to provide accurate and authoritative information with regard to the
subject matter covered herein. It is sold with the clear understanding that the Publisher is not
engaged in rendering legal or any other professional services. If legal or any other expert
assistance is required, the services of a competent person should be sought. FROM A
DECLARATION OF PARTICIPANTS JOINTLY ADOPTED BY A COMMITTEE OF THE
AMERICAN BAR ASSOCIATION AND A COMMITTEE OF PUBLISHERS.
Preface vii
Chapter I Introduction 1
Chapter II Study of the Dynamic Biological Behavior of the
Tumor 3
Chapter III Study of the Dynamic Organization of the Brain 9
Chapter IV Study of the Dynamic Interactions between the
Tumor and the Brain 23
Chapter V Surgical Results 31
Chapter VI Conclusions and Perspectives 33
References 37
Index 85
PREFACE
The rationale of brain tumor surgery depends on two antagonist goals: on one
hand, to optimize the quality of resection, on the other hand, to minimize the risk
of permanent postoperative deficit. However, due to the physiological
interindividual anatomo-functional variability, increased in cases of cerebral
tumors because of the plastic potential of the brain, a study of the interactions
between the lesion and the host seems mandatory – in order to understand the
individual dynamic organization of the brain, then with the goal to avoid
postsurgical sequelae.
In this way, new methods of functional brain mapping can be useful for the
neurosurgeon.
First, before surgery, non-invasive functional neuroimaging techniques
(fMRI, PET, MEG) and invasive extraoperative electrical mapping (subdural
grids) may allow to study the cortical organization for each patient. Furthermore,
Diffusion Tensor Imaging can help to understand the brain connectivity. Thus, the
relationships between the tumor and the eloquent areas can be estimated, and
these data applied to the surgical planning.
Second, during surgery, direct intraoperative electrical stimulation permits to
detect with accuracy and reliability, both the cortical sites and the white pathways
essential for a given function, at each moment and each place of the tumor
removal. Moreover, repeated stimulations all along the surgical act also allow to
study the mechanisms of short-term plasticity, induced by the resection itself. This
on-line mapping is used to tailor the resection according to cortico-subcortical
functional boundaries.
Third, postoperative neurofunctional imaging, combined to the precise
evaluation of the clinical course and the objective assessment of the location and
extent of resection, gives the opportunity to study the mechanisms underlying the
viii Hugues Duffau
functional compensation, i.e. the long-term plasticity. This potential may be used
to perform a second surgery with a better quality of resection than the first one,
thanks to possible brain remapping.
Such a pre-, intra- and post-surgical longitudinal study of dynamic
interactions between brain and lesion, allows to better apprehend the distinct
patterns of functional redistribution for each patient, thus to apply this knowledge
in order:
INTRODUCTION
Since long time, the classical conception of cerebral tumor surgery was to try
to remove a lesion located within a “static” host, i.e. a brain with a functional
organization definitely fixed for each patient and quite similar between patients,
while preserving the structures commonly considered as crucial – namely, the
rolandic, Broca’s and Wernicke’s areas.
In the last decade, technical developments in the field of functional brain
mapping demonstrated the existence of not only a physiological inter-individual
anatomo-functional variability [1,2], but also a plastic potential of the central
nervous system allowing a short- and long-term redistribution of the functional
maps within the same subject, in particular in learning or memory [3,4]: this is the
so-called “natural plasticity”. Moreover, this capacity to reorganize itself was
shown to participate to the functional recovery of patients who presented an acute
cerebral lesion, such as traumatic injury or stroke [5,6]: this is the “post-lesional
plasticity”.
Interestingly, more progressive lesions such as slow-growing tumors are also
able to induce brain functional reshaping [7]. This explains the frequent lack of
neurological deficit despite the growth of infiltrative neoplasms such as low-grade
gliomas within the so-called “eloquent” areas. Consequently, a new conception of
brain tumor surgery could consist on the study of the dynamic interactions
between the natural history of the lesion and the induced cerebral adaptation, in
order to apply this knowledge to each patient and each tumor. Such an attitude
may allow to better select the surgical indications and to maximize the quality of
tumor removal while minimizing the risk of postoperative definitive deficit.
The goal of this article is to review the recent research in brain mapping,
which permits the study of (1) the biological behavior of each tumor, which can
2 Hugues Duffau
change with time (2) the plastic functional brain organization of each patient (3)
and their dynamic interactions – in order to optimize the ratio : benefit / risk of the
cerebral tumor surgery.
Chapter II
A – NATURAL HISTORY
The knowledge of the natural history of a tumor is essential in the optimal
selection of the therapeutical strategy, especially for surgical indications. Among
the spontaneous prognostic factors of brain tumors, in particular concerning
gliomas (i.e. the most frequent tumors of the central nervous system [8,9]), the
biological behavior of the lesion remains one of the more important (or even the
most important) parameter. This includes not only the histological grade of the
tumor and its potential of invasion, but also its ability to change its aggressivity.
One of the best examples is represented by the low-grade gliomas (LGG),
namely the glioma WHO grade II [10]. Indeed, a better understanding of their
natural history shows that LGG can follow three ways of evolution, i.e. (1) local
growth (2) invasion (3) anaplastic transformation. First, recent works have shown
that before any anaplastic transformation, LGG show a continuous, constant
growth of it mean tumor diameter over time, with an average slope around 4 mm
per year [11]. Second, invasion of LGG along the main white matter pathways
within the lesional hemisphere or even controlaterally via the corpus callosum
was also extensively described [12]. Third, it is currently well-known that LGG
systematically changes its biological nature and evolves to a high grade glioma,
with a median of anaplastic transformation estimated around 7 to 8 years,
invariably fatal (median survival around 10 years) [13-36].
This vision of a tumor with a “dynamic” behavior needs to be integrated in
the therapeutical strategy, in order to adapt the treatment both to the actual
4 Hugues Duffau
B - METABOLIC NEUROIMAGING
Indeed, the use of various brain radioactive tracers has shed invaluable light
on the pathophysiology of cerebral neoplasms: nature and degree of heterogeneity
of the tumor, patterns of growth and extension, risk and delay of anaplastic
transformation.
First, Single Photon Emission Computed Tomography (SPECT) studies
showed a relationship between tracers uptake and tumor grade, using both
Thallium-201 [51,52] or 99mTc-MIBI [53-55]. Thus, determination of regions with
the highest metabolic activity within the tumor was used to guide surgical biopsy
in a stereotactic frame [56]. Moreover, SPECT was used in the differential
diagnosis of various brain tumors [58-59], and allowed to differentiate a high-
grade tumor recurrence from radiation necrosis [60]. Some authors also suggested
that 99mTc-MIBI SPECT might help in predicting the response to chemotherapy in
patients with gliomas [61], and in establishing the prognosis of survival after
radiation therapy [62]. However, despite the development of new tracers such as
99m
Tc- Tetrofosmin [63] or 123I-Alpha-Methyl Tyrosine (IMT), potentially useful
for identifying postoperative tumor residue [64] and recurrence [65], SPECT still
lacks reliability, and cannot be used as the sole noninvasive diagnostic or
prognostic tool in brain tumors patients [66].
Second, less widely available and more expensive, Positron Emission
Tomography seems to represent a more reliable and accurate method of metabolic
imaging in brain tumors [67]. Beyond recent studies with positron emitters
presenting definite research interest in molecular imaging [68], e.g. [I-
124]Iododeoxyuridine [69] or [F-18]Fluorothymidine proposed to measure tumor
proliferation rate [70], or FIAU as an indicator of gene expression in glioma
useful for gene therapy [71], most clinical works have focused their efforts on
Study of the Dynamic Biological Behavior of the Tumor 5
energy metabolism [105]. The ranges of Cho increase and NAA decrease seem
compatible with the range of tumor infiltration [106,107]. The calculation of
metabolic maps by integrating the peak area of a metabolite of interest or some
ratios such as the Cho-NAA index for each voxel is currently a common method
to visualize these changes [108-109].
Metabolite profiles have been used to differentiate non-neoplastic lesions
such as inflammation, stroke, multiple sclerosis, gliosis and necrosis [110] from
various types of tumor, which themselves can be distinguished from one another
[111], in particular low-grade gliomas [112] / gliomatosis [113], high grade
gliomas / metastasis [114], meningiomas / hemangiopericytomas [115], and
schwannomas [116]. Metabolite maps have also helped to determine brain tumor
grade [117] and to predict the length of survival [118], notably using : the
phosphocholine / glycerophosphocholine ratio which increases with the grade of
glioma [119]; Cho levels which correlate with proliferative potential as
determined by immunohistochemical analysis of tumors biopsies using the KI-67
labelling index for gliomas [120]; Cho/Cr ratio which increases with grade [111]
while myo-Inositol [121] and Glycine [122] decrease with grade; and the lipids
which correlate with necrosis [123] then are increased in high-grade tumors
[101,124]
Also, this non-invasive method can monitor response to therapy, since the
typical change that occurs when a tumor responds to treatment is a reduction of
Cho with possibly an increase in lactate and/or lipids [125], indicating the
transformation of viable tumor cells towards necrosis. Following radiotherapy,
glioma progression could be predicted on the basis of MRS abnormalities (in
particular an increase of Cho/Cr ratio) that were outside the MRI-defined
treatment region, and can occur prior to subsequent increase in contrast
enhancement [125]. However, the sensitivity of MRS to detect tumor progression
drops when there is a mixture of necrosis and recurrent tumor [126]. The
improved spatial resolution and a more detailed spectral information using higher
field MR systems could optimize the discrimination between radiation damage
and glioma recurrence [127]. Progression to higher grade could be equally
documented using MRS [128].
Moreover, integration of SRM biochemical images of a tumor into a
stereotactic system was proposed both for optimal selection of biopsy target
[107,126,129,130,131] and during tumor resection in order to provide a better
identification of lesion border zones based on metabolic changes due to tumor
infiltration [132-134] (see paragraph dedicated to the image-guided surgery).
SRM was also used to delineate tumor extent for radiation therapy treatment
planning [135-136].
Study of the Dynamic Biological Behavior of the Tumor 7
b) Functional MRI
However, due to the difficulties to routinely use CBF-PET in clinical practice,
many authors participated in the development of fMRI in the preoperative
Study of the Dynamic Organization of the Brain 11
mapping of eloquent areas in the last decade [199-214]. Indeed, fMRI is a widely
available technique using the blood oxygenation level-dependent (BOLD) effect
[215,216], based upon the principle which states that functional increases of
oxygen consumption by neuronal cells induce relative increases of the local
perfusion that exceed the relative oxygen consumption changes – then induce a
decrease of the concentration of deoxygenated hemoglobin generating a higher
signal on T2*-weighted images [217,218] (Fig 1). Furthermore, due to the
improvement of the stimulation paradigms, in particular for language mapping –
by combining multiple tasks and multiple repetition of tasks [203,214] –
successful fMRI mapping can be obtained in routine with a high specificity and an
increased sensitivity [185]. Nevertheless, accumulating evidence seems to indicate
that the BOLD response in the vicinity of a brain tumor does not reflect the
neuronal signal as accurately as it does in healthy tissue [219-222], thus with a
still too low sensitivity [223]. Although poorly understood, the mechanisms seem
not to result from reduced neuronal activity, but rather from an alteration of
neurovascular and metabolic coupling [224,225].
Figure 1. Preoperative fMRI during a motor task of the right upper limb, in a patient without
any neurological deficit, harboring a low-grade glioma involving the left SMA. Interestingly,
while the left central area was activated by the movement of opening / closing the right hand,
there was a bilateral recruitment of both SMA (arrow). This pattern of activation suggests a
preoperative functional reorganization induced by the slow-growing tumor, explaining the
absence of deficit. The reshaping may help to perform a complete surgical resection, despite the
transient occurrence of a postoperative SMA syndrome (from Fontaine, Capelle and Duffau
[557]).
12 Hugues Duffau
c) Magnetoencephalography
Magnetic source imaging (i.e. magnetoencephalography) (MEG), eventually
combined to electroencephalography, is a non-invasive method of measuring
extracranial magnetic fields generated by intraneuronal electric currents [232]. As
magnetic fields are relatively unaffected by the different electrical conductivities
of the brain, cerebrospinal fluid, skull and skin, MEG can accurately localize the
origin of intraneuronal electric currents that contribute to extracranial magnetic
fields [233]. Interestingly, this technique is becoming available at an increasing
number of clinical centers world-wide as an adjunct in the planning and guidance
of brain tumor surgery: indeed, MEG has been extensively used for sensorimotor
[234-242], language [243-246], auditory [247,248] and visual [249,250] mapping.
Furthermore, it was suggested a possible role of MEG as a measure of tumor
infiltration [251], due to a delta and theta activity located close to the lesion, while
a gamma activity was recorded in the controlateral hemisphere [252]. Also, a
correlation between high signal powers in the delta band and the aggressivity of
the tumor was described, because of the structural damage done by the lesion (but
not by the treatment) on the surrounding white/gray matter [253].
in cerebral lesions, due to the loss of structural organization [291]. It seems that
abnormalities on DTI are larger than those seen on T2-weighted images in (high
grade) gliomas, but not in the metastasis [292]. Some authors have suggested that
measurement of fractional anisotropy value could predict histological
characteristics such as cellularity, vascularity and/or fiber structure in astrocytic
tumors [293]. Such a tool for assessing white matter tracts invasion can improve
the targeting of radiation to visible tumor as well as encompassing “invisible”
tumor infiltrating white matter pathways. Second, DTI may distinguish if the
white matter fibers are displaced [294,295], infiltrated or disrupted by the tumor
[296]. Such a knowledge could participate to the selection of the surgical
indications. Third, DTI is able to identify the subcortical connections [297,298],
eventually in a combination with the functional neuroimaging methods [299,300],
then allowing to map the individual anatomo-functional connectivity. These
informations are very useful for the presurgical planning, by delineating the
spatial relationships of the eloquent structures and lesions, in order to preserve the
functional pathways intraoperatively [301-305].
However, this new method needs currently to be validated before it can be
used routinely in surgical procedures [306].
the monitored muscles can be controlled, that is, there is an inability to detect and
possibly avoid motor deficits in nonmonitored muscles. For this reason, Cedzich
et al. suggested that monitoring of « all muscle groups at risk » seemed necessary
[416]. However, in case of wide LGG involving subcortical regions, where the
pyramidal tracts converge (such as the corona radiata and the internal capsule), all
parts of the controlateral hemibody should be controlled, without the possibility to
define before resection some « muscle groups at risk » to monitore - and even
with a loss of the classical somatotopy in the internal capsule in some cases of
insular gliomas, thus with an impossibility to predict which muscles need to be
preferentially controlled at the time of the stimulations. Second, as previouly
mentioned concerning somatosensory evoked potentials, motor evoked potentials
give only indirect information about the location of the pyramidal pathways, even
in case of repetitive stimulations, and do not allow the direct identification of
motor tracts when the resection reaches them. In the same way, although a recent
work showed that a reduction in amplitude larger than 80% and a prolonged
latency more than 15% can be interpreted as intraoperative warning signs of risk
of mechanical damage to the motor system leading to stop the resection [429], the
same authors underlined that the occurence of a complete or nearly complete and
sudden nonartifactual reduction in amplitude could be attributed to a lesion of
subcortical pyramidal fibers, and that these irreversible changes in potential
cannot serve as a warning sign in such cases – because they occur only after the
damage [429]. These limitations of the evoked potential techniques may explain
that still 20% of postoperative definitive deficits, mainly due to resection of
subcortical lesions in the immediate vicinity of the pyramidal tract, have been
reported by Cedzich et al., who concluded that « an additional method is
necessary in patients requiring localization deep in the white matter and when
tumors involving motor pathways are to be removed » [416].
Finally, intraoperative evoked potentials are not currently able to map quickly
and with reliability language, memory and other higher functions.
Consequently, in order to have more time to perform numerous functional
tasks, with the goal to benefit from an extensive, reproducible and reliable cortical
mapping, many authors prone the use of extraoperative electrophysiological
recordings and stimulation via the implantation of subdural grids [432-439].
Using this method, the patient is in optimal conditions, in his room, to perform the
tasks: this point is particularly important for children [440]. Moreover, this
technique permits to identify seizure foci, then to plan the extent of the resection,
in patients who will undergo surgery for intractable epilepsy [441-443]. Finally,
recent advances in the interpretation of the electrophysiological signal, such as
electrocorticographic spectral analysis evaluating the event-related
18 Hugues Duffau
Figure 2. Preoperative anatomical MRI showing a left LGG involving “Broca’s area” (upper
photographs). Intraoperative views before and after resection of the tumor (middle
photographs). Electrical mapping shows a reshaping of the eloquent maps, with a recruitment of
perilesional language sites (i.e. the ventral premotor cortex, dorsolateral prefrontal cortex and
pars orbitaris of the inferior frontal gyrus, marked by the cortical number tags) allowing the
compensation of the “Broca’s area” here removed. In the depth, the resection was continued up
to the contact of the language pathways, in particular the insulo-frontal connections – marked
by the subcortical number tags (from Duffau, Capelle, Sichez et al. [483]). A = Anterior, P =
Posterior. Postsurgical control MRI, demonstrating a complete glioma removal.
resection at this level, both for cortical as well as subcortical structure. The tumor
removal is then performed according to functional boundaries, in order to
optimize the quality of tumor removal while minimizing the risk of postoperative
permanent deficit.
However, DES allows only a loco-regional mapping, and not of the whole
brain, and they are time-consuming, thus with a limitation of the number of tasks
that can be used during surgery.
Therefore, combination with other metabolic and functional non-invasive and
invasive methods seems currently mandatory.
1) Preoperative Plasticity
2) Intraoperative Plasticity
3) Postoperative Plasticity
several patients were examined following the resection of gliomas involving the
supplementary motor area (SMA), which has elicited a transient postsurgical
SMA syndrome (see below). Functional MRI showed in these cases, in
comparison to the preoperative imaging, the occurrence of activations of the SMA
and premotor cortex contralateral to the lesion: the contrahemispheric
homologuous then likely participated to the post-surgical functional compensation
and recovery [542] (Fig 3).
Figure 3. Postoperative fMRI during a motor task of the right upper limb, following a total
resection of a LGG involving the left SMA, which have generated a transient SMA syndrome
then a complete recovery. In addition to a classical activation of the left central area, this fMRI
shows a recruitment of a the controlesional SMA and premotor cortex (arrows), likely
implicated in the postsurgical functional compensation (from Krainik, Duffau, Capelle et al.
[542])
The resection of the frequent LGG invading the SMA [543], namely the
frontomesial area located in front of the primary motor area of the inferior limb,
which is involved in the planning of the movement [544-546], induces the
classical “SMA syndrome” [209,431,465,547-553]. This syndrome is
characterized by a complete akinesia and even mutism in cases of lesions of the
left dominant SMA, which occurs approximately thirty minutes following the end
of the resection, as observed in awake patients [554]. Then, this syndrome
suddenly and spontaneously resolves around the tenth day following surgery, even
if some rehabilitation is often needed during 1 to 3 months in order to allow a real
complete functional recovery.
Using preoperative fMRI, it was shown that the occurrence of this syndrome
is not related to the volume of the frontal resection, but directly to the removal of
this specific structure called the “SMA-proper”, detectable on the preoperative
functional neuroimaging (Fig 1). Thus, on the basis of the presurgical fMRI, it is
now possible to predict, before surgery, if a SMA syndrome will occur or not
postoperatively, and to inform the patient and his family [555,556].
Moreover, by coupling preoperative fMRI, the pattern of clinical deficit after
surgery, and the extent of resection on the postoperative MRI, it was demonstrated
the existence of a somatotopy within the SMA-proper – namely, from anterior to
posterior: the representation of language (at least in the dominant hemisphere), the
one of the face, then the superior limb, then the inferior limb (just in front of the
paracentral lobule) [557]. Thus, it is possible to predict before surgery the severity
and the pattern of the postoperative transient deficit, for instance only mutism, or
mutism and akinesia of the superior limb, or akinesia of the entire hemibody. This
has an important impact concerning the planning of a specific rehabilitation.
In the same way, it was regularly possible to remove gliomas involving the
pars opercularis and pars triangularis of the left inferior frontal gyrus, namely
Broca’s area, without generating any aphasia, due to a perilesional reorganization
of language areas, in particular in the ventral premotor cortex – an area
demonstrated to play a major role in articulation [491] – behind the lesion and in
the pars orbitaris of the inferior frontal gyrus in front of the glioma (as
demonstrated by electrical stimulations, which also allowed the preservation of
the insula and subcortical language pathways in the depth of the cavity [7]) (Fig
2).
28 Hugues Duffau
It was also possible to remove the primary sensorimotor area of the face
without eliciting permanent postoperative central facial palsy, but only within the
non-dominant hemisphere [566]. In these cases, the subcortical motor sites which
represented the deep functional boundaries of the resection, corresponded to the
pyramidal pathways of the upper limb, running under the representation of the
face previously removed [492].
7) Other Locations
To be mentioned that this list is not exhaustive, and that gliomas involving
other “eloquent” regions have been also removed without generating permanent
neurological deficit, owing to the compensatory ability of the brain studied using
Study of the Dynamic Interactions between the Tumor and the Brain 29
pre- and intra-operative functional mapping methods, e.g. tumor invading the
frontal eye fields [570-572], the left angular gyrus despite its implication in
calculation [573], the left dominant postero-temporal regions near the
“Wernicke’s area” [574,575], the regions involved in writing [576], reading [577],
bilinguism [578,579], or even control of micturition [580].
SURGICAL RESULTS
A – FUNCTIONAL RESULTS
The integration of individual functional mapping, connectivity and plasticity
in the surgical decision and planning has permitted first to extend the indications
of surgery for tumors located in areas considered until now as “inoperable” [582].
Moreover, despite a frequent but transient immediate postoperative functional
worsening (due to the attempt to perform a maximal tumor removal), in a delay of
3 months following the surgery, 95% of patients recovered a normal neurological
examination, even with a possible improvement in comparison with their
preoperative status [241,307,309,455-457,459,463,465,468,473-
476,484,485,501,551,582-585] – and also with a significant decrease of seizures
in 80% of patients with preoperative chronic epilepsia [561]. All these patients
returned to a normal socio-professional life.
Interestingly, in comparison, in series which did not use intraoperative
electrical mapping, the rate of sequelae ranged from 13 to 27.5%, with a mean
around 19 % [586-593].
32 Hugues Duffau
B – NEURO-ONCOLOGICAL RESULTS
Since mapping techniques allow to identify the cortical and subcortical
eloquent structures individually, it seems logical to perform a resection according
to functional boundaries. Indeed, it has been suggested to continue the resection
until the functional structures are detected by DES, and not before, in order to
optimize the quality of resection – without increasing the risk to generate
postoperative permanent deficit [492,582]. This surgical strategy permits a
significative improvement of the quality of tumor removal, despite a higher
number of surgeries within critical areas, and a parallel decrease of the rate of
sequelae [582].
Moreover, while extensive surgery is still controversial, in particular
regarding low-grade gliomas, the current surgical results support the positive
impact of such a “maximalist” treatment strategy, i.e. with a likely benefit on the
natural history of the tumors which seems to be related to the quality of resection
[582]: these results are in accordance with the recent surgical series of the
literature [583,594-606].
Chapter VI
Brain tumor surgery may now benefit from a better understanding of (1) the
dynamic biological behavior of the tumor (2) the dynamic organization of the
brain (3) the dynamic interactions between the growth, extension ± anaplastic
transformation of the glioma and the reactional plastic phenomena of the nervous
system allowing a functional compensation of the damage induced by the lesion
and even by the surgical act itself.
Indeed, this better knowledge is currently possible owing to the important
technical developments in the field of metabolic and functional mapping, using
both non-invasive methods of neuroimaging and intraoperative
electrophysiological investigations. Furthermore, recent progress in neurosciences
allow to integrate new concepts about the functioning of the central nervous
system in the surgical strategy, namely: the study of individual functional brain
organization, of anatomo-functional connectivity, and brain plasticity potential.
All these recent advances are useful for the neurosurgeon, since they allow
(1) the extension of surgical indications, in particular in eloquent brain areas ; (2)
a better quality of glioma resection with a greater neuro-oncological impact ; and
(3) a minimization of the risk of postoperative sequelae, with preservation of the
quality of life.
Several perspectives could be considered to continue to improve brain surgery
in eloquent regions.
34 Hugues Duffau
2) Pathophysiological Perspectives
3) Surgical Perspectives
The first goal is to better select the surgical indications in brain tumors. It
necessitates to increase the homogeneity and the follow-up of surgical series, and
to elaborate prospective studies in order to better evaluate the actual impact on the
natural history of tumors, in particular LGG.
When surgery is decided, the aim is to optimize the Benefit / Risk ratio. On
the basis of the results previously detailed, it seems necessary to use brain
mapping methods, in order to detect then preserve the essential functional areas,
Conclusions and Perspectives 35
4) Oncological Perspectives
5) Quality of Life
Finally, it is mandatory to better evaluate the quality of life [613]. In this way,
it is essential first to improve the pre- intra- and post-operative functional
assessments, namely neurological, neuropsychological and language examinations
by specialists, second to develop objective and subjective scales of evaluation by
the patient himself and his family.
Thus, multidisciplinar multicenter studies are necessary in order to better
understand the dynamic interactions between cerebral function (i.e., the host),
tumor evolution and treatments, with the goal to optimize the therapeutic strategy
in brain tumors.
REFERENCES
[11] Mandonnet E, Delattre JY, Tanguy ML, et al. Continuous growth of mean
tumor diameter in a subset of grade II gliomas. Ann Neurol 2003; 53 : 524-
8.
[12] Giese A, Bjerkvig R, Berens ME, Westphal M. Cost of migration: invasion
of malignant gliomas and implications for treatment. J Clin Oncol 2003; 21:
1624-36.
[13] Afra D, Osztie E, Sipos L, et al. Preoperative history and postoperative
survival of supratentorial low-grade astrocytomas. Br J Neurosurg 1999 ;
13 : 299-305.
[14] Arienti VM, Botturi A, Boiardi A, et al. Adult brain low-grade
astrocytomas: survival after surgery and radiotherapy. Neurol Sci 2001 ;
22 : 233-8.
[15] Ashby LS, Shapiro WR. Low-grade glioma: supratentorial astrocytoma,
oligodendroglioma, and oligoastrocytoma in adults. Curr Neurol Neurosci
Rep 2004 ; 4 : 211-7.
[16] Bahary JP, Villemure JG, Choi S, et al. Low-grade pure and mixed cerebral
astrocytomas treated in the CT scan era. J Neurooncol 1996 ; 27 : 173-7.
[17] Bauman G, Lote K, Larson D, et al. Pretreatment factors predict overall
survival for patients with low-grade gliomas: a recursive partitioning
abalysis. Int J Radiat Oncol Biol Phys 1999 ; 45 : 923-9.
[18] Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy
versus radiotherapy plus CCNU for incompletely resected low-grade
gliomas : a Southwest Oncology Group study. J Neurosurg 1993 ; 78 : 909-
14.
[19] Firsching R, Tieben R, Schröder R, et al. Long-term prognosis of low-grade
astrocytoma. Zentralbl Neurochir 1994 ; 55 : 10-5.
[20] Janny P, Cure H, Mohr M, et al. Low grade supratentorial astrocytomas.
Management and prognostic factors. Cancer 1994 ; 73 : 1937-45.
[21] Kaye AH, Walker DG. Low-grade astrocytomas: controversies in
management. J Clin Neurosci 2000 ; 7 : 475-483.
[22] Lindegaard KF, Mork SJ, Eide GE, et al. Statistical analysis of
clinicopathological features, radiotherapy and survival in 170 cases of
oligodendroglioma. J Neurosurg 1987 ; 67 : 224-30.
[23] McCormack BM, Miller DC, Budzilovich GN, et al. Treatment and survival
of low-grade astrocytoma in adults – 1977-1988. Neurosurgery 1992 ; 31 :
636-42.
[24] Nakamura M, Konishi N, Tsunoda S, et al. Analysis of proignostic and
survival factors related to treatment of low-grade astrocytomas in adults.
Oncology 2000 ; 58 : 108-16.
References 39
[88] Chung JK, Kim YK, Kim SK, et al. Usefulness of 11C-methionine PET in
the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG
PET. Eur J Nucl Med Mol Imaging 2002; 29: 176-82.
[89] Derlon JM, Chapon F, Noel MH, et al. Non-invasive grading of
oligodendrogliomas: correlation between in vivo metabolic pattern and
histology. Eur J Nucl Med 2000; 27: 778-87.
[90] De Witte O, Goldberg I, Wikler D, et al. Positron emission tomography
with injection of methionine as a prognostic factor in glioma. J Neurosurg
2001; 95: 746-50.
[91] Derlon JM, Petit-Taboue MC, Chapon F, et al. The in vivo metabolic
pattern of low-grade brain gliomas: a positron emission tomographic study
using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. Neurosurgery
1997; 40: 276-87.
[92] Herholz K, Hölzer T, Bauer B, et al. 11C-methionine PET for differential
diagnosis of low-grade gliomas. Neurology 1998; 50 :1316-22.
[93] Ribom D, Eriksson A, Hartman M, et al. Positron emission tomography
(11)C-methionine and survival in patients with low-grade gliomas. Cancer
2001; 92: 1541-9.
[94] Pirotte B, Goldman S, Massager N, et al. Combined use of 18F-
flurodeoxyglucose and 11C-methionine in 45 positron emission
tomographye-guided stereotactic brain biopsies. J Neurosurg 2004; 101:
476-83.
[95] Voges J, Herholz K, Holzer T, et al. 11C-methionine and 18F-2-
fluorodeoxyglucose positron emission tomography: a tool for diagnosis of
cerebral glioma and monitoring after brachytherapy with 125I seeds.
Stereotact Funct Neurosurg 1997; 69: 129-35.
[96] Derlon JM, Bourdet C, Bustany P, et al. [11C]L-methionine uptake in
gliomas. Neurosurgery 1989; 25: 720-8.
[97] Inoue T, Shibasaki T, Oriuchi N, et al. 18F alpha-methyl tyrosine PET
studies in patients with brain tumors. J Nucl Med 1999; 40: 399-405.
[98] Menedez J, Nanda A, Polin RS. PET scan for brain tumors. Sem Neurosurg
2000; 11: 277-86.
[99] de Edelenyi FS, Rubin C, Esteve F, et al. A new approach for analyzing
proton magnetic resonance spectroscopic images of brain tumors: nosologic
images. Nat Med 2000; 6: 1287-9.
[100] Herminghaus S, Pilatus U, Moller-Hartman W, et al. Increased choline
levels coincide with enhanced proliferative activity of human
neuroepithelial brain tumors. NMR Biomed 2002; 15:385-92.
References 45
[101] Negendank WG, Sauter R, Brown TR, et al. Proton magnetic resonance
spectroscopy in patients with glial tumours: a multicenter study. J
Neurosurg 1996; 84: 449-58.
[102] Howe FA, Barton SJ, Cudlip SA, et al. Metabolic profiles of human brain
tumors using quantitative in vivo 1H magnetic resonance spectroscopy.
Magn Reson med 2003; 49: 223-32.
[103] Michaelis T, Merboldt KD, Bruhn H, Hanicke W, Frahm J. Absolute
concentrations of metabolites in the adult human brain in vivo:
quantification of localized proton MR spectra. Radiology 1993; 187: 219-
27.
[104] Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic
resonance spectroscopy unambiguously identifies different neural cell types.
J Neurosci 1993; 13: 981-9.
[105] Kemp GJ. Non-invasive methods for studying brain energy metabolism:
what they show and what it means. Dev Neurosci 2000; 22: 418-28.
[106] Croteau D, Scarpace L, Hearshen D, et al. Correlation between magnetic
resonance spectroscopy imaging and image-guided biopsies:
semiquantitative and qualitative histopathological analyses of patients with
untreated glioma. Neurosurgery 2001;49:823-9.
[107] Dowling C, Bollen AW, Noworolski SM, et al. Preoperative proton MR
spectroscopy imaging of brain tumors: correlation with histopathologic
analysis of resection specimens. Am J Neuroradiol 2001; 22: 604-12.
[108] McKnight TR, Noworolski SM, Vigneron DB, Nelson SJ. An automated
technique for the quantitative assessment of 3D-MRSI data from patients
with glioma. J Magn Reson Imag 2001; 13: 167-77.
[109] Tate AR, Griffiths JR, Martinez-Perez I, et al. Towards a method for
automated classification of 1H MRS spectra from brain tumours. NMR
Biomed 1998; 11: 177-91.
[110] Butzen J, Prost R, Chetty V, et al. Discrimination between neoplastic and
nonneoplastic brain lesions by use of proton MR spectroscopy: the limits of
accuracy with a logistic regression model. Am J Neuroradiol 2000; 21:
1213-9.
[111] Howe FA, Opstad KS. 1H MR spectroscopy of brain tumours and masses.
NMR Biomed 2003; 16: 123-31.
[112] Pirzkall A, Nelson SJ, McKnight TR, et al. Metabolic imaging of low-grade
gliomas with three-dimensional magnetic resonance spectroscopy. Int J
Radiat Oncol Biol Phy. 2002; 53: 1254-64.
46 Hugues Duffau
[138] Pomper MG, Port JD. New techniques in MR imaging of brain tumors.
Magn Reson Imaging Clin N Am 2000; 8: 691-713.
[139] Rees J. Advances in magnetic resonance imaging of brain tumours. Curr
Opin Neurol 2003; 16: 643-50.
[140] Keston P, Murray AD, Jackson A. Cerebral perfusion imaging using
contrast-enhanced MRI. Clin Radiol 2003; 58: 505-13.
[141] Le Bihan D. Looking into the functional architecture of the brain with
diffusion MRI. Nat Rev Neurosci 2003; 4: 469-80.
[142] Kono K, Inoue Y, Nakayama K, et al. The role of diffusion-weighted
imaging in patients with brain tumors. AJNR Am J Neuroradiol 2001; 22:
1081-8.
[143] Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted
MRI with echo-planar technique in the evaluation of cellularity in gliomas.
J Magn Reson Imaging 1999; 9: 53-60.
[144] Yang D, Korogi Y, Suguhara T, et al. Cerebral gliomas: prospective
comparison of multivoxel 2D chemical-shift imaging proton MR
spectroscopy, echoplanar perfusion and diffusion-weighted MRI.
Neuroradiology 2002; 44: 656-66.
[145] Kim YJ, Chang KH, Song IC, et al. Brain abscess and necrotic or cystic
brain tumor: discrimination with signal intensity on diffusion-weighted MR
imaging. Am J Roentgenol 1998; 171: 1487-90.
[146] Chang SC, Lai PH, Chen WL, et al. Diffusion-weighted MRI features of
brain abscess and cystic or necrotic brain tumors: comparison with
conventional MRI. Clin Imaging 2002; 26: 227-36.
[147] Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-
determined cerebral blood volume maps with histological and angiographic
determination of vascularity of gliomas. Am J Roentgenol 1998; 171: 1479-
86.
[148] Lefournier V, Peoc’h M, Usson Y, et al. Magnetic resonance cerebral blood
volume maps. Comparison with histologic findings in different types of
brain lesions. J Neuroradiol 2003; 30: 3-9.
[149] Roberts HC, Roberts TP, Brasch RC, Dillon WP. Quantitative measurement
of microvascular permeability in human brain tumors achieved using
dynamic contrast-enhanced MR imaging: correlation with histologic grade.
Am J Neuroradiol 2000; 21: 891-99.
[150] Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-
enhanced T2*-weighted MR imaging. Radiology 1999; 211: 791-8.
References 49
[206] Krings T, Reinges MH, Erberich S,et al. Functional MRI for presurgical
planning: problems, artefacts, and solution strategies. J Neurol Neurosurg
Psychiatry 2001; 70: 749-60.
[207] Lee CC, Ward HA, Sharbrough FW, et al. Assessment of functional MR
imaging in neurosurgical planning. Am J Neuroradiol 1999; 20: 1511-9.
[208] Mueller WM, Yetkin FZ, Hammeke TA, et al. Functional magnetic
resonance imaging mapping of the motor cortex in patients with cerebral
tumors. Neurosurgery 1996; 39: 515-20.
[209] Nelson L, Lapsiwala S, Haughton VM, et al. Preoperative mapping of the
supplementary motor area in patients harbouring tumors in the medial
frontal lobe. J Neurosurg 2002; 97: 1108-14.
[210] Nitschke MF, Melchert UH, Hahn C. Preoperative functional magnetic
resonance imaging (fMRI) of the motor system in patients with tumours in
the parietal lobe. Acta Neurochir (Wien) 1998; 140: 1223-9.
[211] Pujol J, Conesa G, Deus J, et al. Presurgical identification of the primary
sensorimotor cortex by functional magnetic resonance imaging. J
Neurosurg 1996; 84: 7-13.
[212] Roux FE, Boulanouar K, Ranjeva JP, et al. Usefulness of motor functional
MRI correlated to cortical mapping in Rolandic low-grade astrocytomas.
Acta Neurochir (Wien) 1999; 141: 71-9.
[213] Righini A, de Divitiis O, Prinster A, et al. Functional MRI: primary motor
cortex localization in patients with brain tumors. J Comput Assist Tomogr
1996; 20: 702-8.
[214] Rutten GJ, Ramsey NF, van Rijen PC, Noordmans HJ, van Veelen CW.
Development of a functional magnetic resonance imaging protocol for
intraoperative localization of critical temporoparietal language areas. Ann
Neurol 2002; 51: 350-60.
[215] Belliveau JW, Rosen BR, Kantor HL, et al. Functional cerebral imaging by
susceptibility-contrast NMR. Mag Reson Med 1990; 14: 538-46.
[216] Ogawa S, Menon RS, Tank DW, et al. Functional brain mapping by blood
oxygenation level-dependent contrast magnetic resonance imaging. A
comparison of signal characteristics with a biophysical model. Biophys J
1993; 64: 803-812.
[217] HeegerDJ, Ress D. What does fMRI tell us about neuronal activity? Nat Rev
Neurosci 2002; 3: 142-51.
[218] Toronov V, Walker S, Gupta R, et al. The roles of changes in deoxy-
hemoglobin concentration and regional cerebral blood volume in the fMRI
BOLD signal. Neuroimage 2003; 19: 1521-31.
54 Hugues Duffau
[219] Holodny AI, Schulder WC, Liu JA, Maldjian JA, Kalnin AJ. Decreased
BOLD functional MR activation of the motor and sensory cortices adjacent
to a glioblastoma multiforme: implications for image-guided neurosurgery.
Am J Neuroradiol 1999; 20: 609-12.
[220] Holodny AI, Schulder WC, Liu J, Wolko JA, Maldjian, Kalnin AJ. The
effect of brain tumors on BOLD functional MR Imaging activation in the
adjacent motor cortex: implications for image-guided neurosurgery. Am J
Neuroradiol 2000; 21: 1415-22.
[221] Ulmer JL, Krouwer HG, Mueller WM, Ugurel MS, Kocak M, Mark LP.
Pseudo-reorganization of language cortical function at fMR imaging: a
consequence of tumor-induced neurovascular uncoupling. Am J
Neuroradiol 2003; 24: 213-17.
[222] Ulmer JL, Hacein-Bey L, Mathews VP, et al. Lesion-induced pseudo-
dominance at functional magnetic resonance imaging: implications for
preoperative assessments. Neurosurgery 2004; 55: 569-79.
[223] Roux FE, Boulanouar K, Lotterie JA, mejdoubi M, LeSage JP, Berry I.
Language functional magnetic resonance imaging in preoperative
assessment of language areas: correlation with direct cortical stimulation.
Neurosurgery 2003; 52: 1335-45.
[224] Schreiber AU, Hubbe U, Ziyeh S, Hennig J. The influence of gliomas and
nonglial space-occupying lesions on blood-oxygen-level-dependent contrast
enhancement. Am J Neuroradiol 2000; 21: 1055-63.
[225] Aubert A, Costalat R, Duffau H, Benali H. Modeling of pathophysiological
coupling between brain electrical activation, energy metabolism and
hemodynamics: insights for the interpretation of intracerebral tumor
imaging. Acta Biotheoretica 2002; 50: 281-95.
[226] Boas DA, Dale AM, Franceschini MA. Diffuse optical imaging of brain
activation : approaches to optimizing image sensitivity, resolution and
accuracy. NeuroImage 2004; 23: 275-88.
[227] Franceschini MA, Boas DA. Noninvasive measurement of neuronal activity
with near-infrared optical imaging. NeuroImage 2004; 21: 336-72.
[228] Wolf M, Wolf U, Toronov V, et al. Different time evolution of
oxyhemoglobin and deoxyhemoglobin concentration changes in the visual
and motor cortices during functional stimulation: a near-infrared
spectroscopy study. NeuroImage 2002; 16: 704-12.
[229] Fujiwara N, Sakatani K, Katayama Y, et al. Evoked-cerebral blood
oxygenation changes in false-negative activations in BOLD contrast
functional MRI of patients with brain tumors. NeuroImage 2004; 21: 1464-
71.
References 55
[242] Sobel DF, Galen CC, Schwartz BJ, et al. Locating the central sulcus:
comparison of MR anatomic and magnetoencephalographic functional
methods. Am J Neuroradiol 1993; 14: 915-25.
[243] Castillo EM, Simos PG, Venkataraman V, Breier JI, Wheless JW,
Papanicolaou AC. Mapping of expressive language cortex using magnetic
source imaging. Neurocase 2001; 7: 419-22.
[244] Maestu F, Ortiz T, Fernandez A, et al. Spanish language mapping using
MEG: a validation study. Neuroimage 2002; 17: 1579-86.
[245] Papanicolaou AC, Simos PG, Breier JI, et al. Magnetoencephalographic
mapping of the language-specific cortex. J Neurosurg 1999; 90: 85-93.
[246] Simos PG, Papanicolaou AC, Breier JI, et al. Localization of language-
specific cortex by using magnetic source imaging and electrical stimulation
mapping. J Neurosurg 1999; 91: 787-96.
[247] Nakasato N, Kumabe T, Kanno A, Ohtomo S, Mizoi K, Yoshimoto T.
Neuromagnetic evaluation of cortical auditory function in patients with
temporal lobe tumors. J Neurosurg 1997; 86: 610-8.
[248] Stippich C, Freitag P, Kassubek J, et al. Motor, somatosensory and auditory
cortex localization by fMRI and MEG. Neuroreport 1998; 9: 1953-7.
[249] Nakasato N, Seki K, Fujita S, et al. Clinical application of visual evoked
fields using an MRI-linked whole head MEG system. Frontiers Med Biol
Engng 1996; 7: 275-83.
[250] Nakasato N, Yoshimito T. Somatosensory, auditory, and visual evoked
magnetic fields in patients with brain diseases. J Clin Neurophysiol 2000;
17: 201-11.
[251] Roberts TPL, Tran Q, Ferrari P, Berger MS. Increased somatosensory
neuromagnetic fields ipsilateral to lesions in neurosurgical patients.
Neuroreport. 2002; 13: 699-702.
[252] de Jongh A, de Munck JC, Baayen JC, Jonkman EJ, Heethaar RM, van Dijk
BW. The localization of spontaneous brain activity: first results in patients
with cerebral tumors. Clin Neurophysiol 2001; 112: 378-85.
[253] de Jongh A, Baayen JC, de Munck JC, Heethaar RM, Vandertop WP, Stam
CJ. The influence of brain tumor treatment on pathological delta activity in
MEG. Neuroimage 2003; 20: 2291-301.
[254] Black P, Jaaskelainen J, Chabrerie A, Golby A, Gugino L. Minimalist
approach: functional mapping. Clin Neurosurg 2002; 49: 90-102.
[255] Chabrerie A, Nabavi A, Ozlen F, et al. Three-dimensional reconstruction for
cortical surgery: the Brigham and Women’s Hospital experience. Tech
Neurosurg 2001; 7: 61-9
References 57
[269] Benson RR, FitzGerald DB, LeSueur LL, et al. Language dominance
determined by whole brain functional MRI in patients with brain lesions.
Neurology 1999; 52: 798-809.
[270] Breier JI, Simos PG, Zouridakis G, et al. Language dominance determined
by magnetic source imaging. A comparison with the Wada procedure.
Neurology 1999; 53: 938-45.
[271] Breier JI, Simos PG, Zouridakis G, Papanicolaou AC. Lateralization of
activity associated with language function using magnetoencephalography.
A reliability study. J Clin Neurophysiol 2000; 17: 503-10.
[272] Hirata M, Kato A, Taniguchi M, et al. Determination of language
dominance with synthetic aperture magnetometry: comparison with the
Wada test. Neuroimage 2004; 23: 46-53.
[273] Kober H, Möller M, Nimsky C, Vieth J, Fahlbusch R, Ganslandt O. New
approach to localize speech relevant brain areas and hemispheric dominance
using spatially filtered magnetoencephalography. Hum Brain Mapping
2001; 14: 236-50.
[274] Lehéricy S, Cohen L, Bazin B, et al. Functional MR evaluation of temporal
and frontal language dominance compared with the Wada test. Neurology
2000; 54: 1625-33.
[275] Papanicolaou AC, Simos PG, Castillo EM, et al. Magnetocephalography: a
noninvasive alternative to the Wada procedure. J Neurosurg 2004; 100:
867-76.
[276] Simos PG, Breier JI, Zouridakis G, Papanicolaou PG. Assessment of
functional cerebral laterality for language using magnetoencephalography. J
Clin Neurophysiol 1998; 15: 364-72.
[277] Szymanski MD, Perry DW, Gage NM, et al. Magnetic source imaging of
late evoked field responses to vowels: toward an assessment of hemispheric
dominance for language. J Neurosurg 2001; 94: 445-53.
[278] Kamada K, Takeuchi F, Kuriki S, Oshiro O, Houkin K, Abe H. Functional
neurosurgical simulation with brain surface magnetic resonance images and
magnetoencephalography. Neurosurgery 1993; 33: 269-72.
[279] Clark CA, Barrick TR, Murphy MM, Bell BA. White matter fiber tracking
in patients with space-occupying lesions of the brain: a new technique for
neurosurgical planning? Neuroimage 2003; 20: 1601-8.
[280] Basser PJ, Mattiello J, LeBihan D. Estimation of the effective self-diffusion
tensor from the NMR spin echo. J Magn Reson B 1994; 103: 247-54.
[281] Basser PJ, Pajevic S, Pierpaoli C, Duda J, Aldroubi A. In vivo fiber
tractography using DT-MRI data. Magn Res Med 2000; 44: 625-32.
References 59
[282] Catani M, Howard RJ, Pajevic S, Jones DK. Virtual in vivo interactive
dissection of white matter fasciculi in the human brain. Neuroimage 2002;
17: 77-94.
[283] Conturo TE, Lori NF, Cull TS, et al. Tracking neuronal fiber pathways in
the living human brain. Proc Natl Acad Sci USA 1999; 96: 10422-7.
[284] Mori S, Crain BJ, Chacko VP, van Zijl PC. Three-dimensional tracking of
axonal projections in the brain by magnetic resonance imaging. Ann Neurol
1999; 45: 265-9.
[285] Mori S, van Zijl PC. Fiber tracking principles and strategies: a technical
review. NMR Biomed 2002; 15: 468-80.
[286] Pierpaoli C, Basser PJ. Toward a quantitative assessment of diffusion
anisotropy. Magn Reson Med 1996; 36: 893-906.
[287] Pajevic S, Pierpaoli C. Color schemes to represent the orientation of
anisotropic tissues from diffusion tensor data: application to white matter
fiber tract mapping in the human brain. Magn Reson Med 1999; 42: 526-40.
[288] Poupon C, Clark CA, Frouin V, et al. Regularization of diffusion-based
direction maps for the tracking of brain white matter fascicles. Neuroimage
2000; 12: 184-95.
[289] Lu S, Ann D, Johnson G, Cha S. Peritumoral diffusion tensor imaging of
high-grade gliomas and metastatic brain tumors. Am J Neuroragiol 2003;
24: 937-41.
[290] Sinha S, Bastin ME, Whittle IR, Wardlaw JM. Diffusion tensor MR
Imaging of high-grade cerebral gliomas. Am J Neuroradiol 2002; 23: 520-7.
[291] Wieshmann UC, Clark CA, Symms MR, et al. Reduced anisotropy of water
diffusion in structural cerebral abnormalities demonstrated with diffusion
tensor imaging. Magn Reson Imaging 1999; 17: 1269-74.
[292] Price SJ, Burnet NG, Donovan T, et al. Diffusion tensor imaging of brain
tumors at 3 T : a potential tool for assessing white matter tract invasion?
Clin Radiol 2003; 58: 455-62.
[293] Beppu T, Inoue T, Shibata Y, et al. Measurement of fractional anisotropy
using diffusion tensor MRI in supratentorial astrocytic tumors. J
Neurooncol 2003; 63: 109-16.
[294] Gossl C, Fahrmeir L, Putz B, Auer LM, Auer DP. Fiber tracking from DTI
using linear state space models: detectability of the pyramidal tract.
Neuroimage 2002; 16: 378-88.
[295] Wieshmann UC, Symms MR, Parker GJ, et al. Diffusion tensor imaging
demonstrates deviation of fibres in normal appearing white matter adjacent
to a brain tumour. J Neurol Neurosurg Psychiatry 2000; 68: 501-3.
60 Hugues Duffau
[319] Rezai AR, Mogilner AY, Cappell J, Hund M, Llinas RR, Kelly PJ.
Integration of functional brain mapping in image-guided neurosurgery. Acta
Neurochir Suppl (Wien) 1997; 68: 85-9.
[320] Coenen VA, Krings T, Mayfrank L, et al. Three-dimensional visualization
of the pyramidal tract in a neuronavigation system during brain tumor
surgery: first experiences and technical note. Neurosurgery 2001; 49: 86-92.
[321] Coenen VA, Krings T, Axer H, et al. Intraoperative three-dimensional
visualization of the pyramidal tract in a neuronavigation system (PTV)
reliably predicts true position of principal motor pathways. Surg Neurol
2003; 60: 381-90.
[322] Holodny AI, Schwartz TH, Ollenschleger M, Liu WC, Schulder M. Tumor
involvement of the corticospinal tract: diffusion magnetic resonance
tractography with intraoperative correlation. J Neurosurg 2001; 95: 1082.
[323] Möller-Hartmann W, Krings T, Coenen VA, et al. Preoperative assessment
of motor cortex and pyramidal tracts in central cavernoma employing
functional and diffusion-weighted magnetic resonance imaging. Surg
Neurol. 2002; 58: 302-7.
[324] Jannin P, Morandi X, Fleig OJ, et al. Integration of sulcal and functional
information for multimodal neuronavigation. J Neurosurg 2002; 96: 713-23.
[325] McDonald JD, Chong BW, Lewine JD, et al. Integration of preoperative and
intraoperative functional brain mapping in a frameless stereotactic
environment for lesions near eloquent cortex. Technical note. J Neurosurg
1999; 90: 591-8.
[326] Nimsky C, Ganslandt O, Kober H, et al. Integration of functional magnetic
resonance imaging supported by magnetoencephalography in functional
neuronavigation. Neurosurgery 1999; 44: 1249-55.
[327] Sabbah P, Foehrenbach H, Dutertre G, et al. Multimodal anatomic,
functional and metabolic brain imaging for tumor resection. Clin Imaging
2002; 26: 6-12.
[328] Kamada K, Houkin K, Takeuchi F, et al. Visualization of the eloquent
motor system by integration of MEG, functional and anisotropic diffusion-
weighted MRI in functional neuronavigation. Surg Neurol 2003; 59: 353-
62.
[329] Aoyama H, Kamada K, Shirato H, et al. Integration of functional brain
information into stereotactic irradiation treatment planning using
magnetoencephalography and magnetic resonance axonography. Int J
Radiat Oncol Biol Phys 2004; 58: 1177-83.
References 63
[330] Dorward NL, Alberti O, Palmer JD, Kitchen ND, Thomas DGT. Accuracy
of true frameless stereotaxy: in vivo measurement and laboratory phantom
studies. J Neurosurg 1999; 90: 160-68.
[331] Gumprecht HK, Widenka DC, Lumenta CB. BrainLab VectorVision
neuronavigation system: technology and clinical experience in 131 cases.
Neurosurgery 1999; 44: 97-105.
[332] Hartkens T, Hill DL, Castellano-Smith AD, et al. Measurement and analysis
of brain deformation during neurosurgery. IEEE Trans Med Imaging 2003;
22: 82-92.
[333] Hill DL, Maurer CR Jr, Maciunas RJ, Barwise JA, Fitzpatrick JM, Wang
MY. Measurement of intraoperative brain surface deformation under a
craniotomy. Neurosurgery 1998; 43: 514-26.
[334] Navabi A, Black PMcL, Gering DT, et al. Serial intraoperative MR imaging
of brain shift. Neurosurgery 2001; 48: 787-98.
[335] Reinges MH, Nguyen HH, Krings T, Hutter BO, Rohde V, Gilsbach JM.
Course of brain shift during microsurgical resection of supratentorial
cerebral lesions: limits of conventional neuronavigation. Acta Neurochir
(Wien) 2004; 146: 369-77.
[336] Roberts DW, Hartov A, Kennedy FE, Miga MI, Paulsen KD. Intraoperative
brain shift and deformation: a quantitative analysis of cortical displacement
in 28 cases. Neurosurgery 1998; 43: 749-58.
[337] Comeau RM, Sadikot AF, Fenster A, Peters TM. Intraoperative ultrasound
for guidance and tissue shift correction in image-guided neurosurgery. Med
Phys 2000; 27: 787-800.
[338] Giorgi C, Casolino DS. Preliminary clinical experience with intraoperative
stereotactic ultrasound imaging. Stereotact Funct Neurosurg 1997; 68: 54-8.
[339] Gronningsaeter A, Kleven A, Ommedal S, et al. SonoWand, an ultrasound-
based neuronavigation system. Neurosurgery 2000; 47: 1373-9.
[340] Jodicke A, Deinsberger W, Erbe H, Kriete A, Boker DK. Intraoperative
three-dimensional ultrasonography: an approach to register brain shift using
multidimensional image processing. Minim Invasive Neurosurg 1998; 41:
13-9.
[341] Keles GE, Lamborn KR, Berger MS. Coregistration accuracy and detection
of brain shift using intraoperative sononavigation during resection of
hemispheric tumors. Neurosurgery 2003; 53: 556-564.
[342] Lindseth F, Lango T, Bang J, Nagelhus Hernes TA. Accuracy evaluation of
a 3D ultrasound-based neuronavigation system. Comput Aided Surg 2002;
7: 197-222.
64 Hugues Duffau
[384] Hall WA, Liu H, Martin AJ, Pozza CH, Maxwell RE, Truwit CL. Safety,
efficacy, and functionality of high-field-strengh interventional magnetic
resonance imaging fir neurosurgery. Neurosurgery 2000; 46: 632-42.
[385] Martin AJ, Hall WA, Liu H, et al. Brain tumor resection: intraoperative
monitoring with high-field-strength MR imaging-initial results. Radiology
2000; 215: 221-8.
[386] Sutherland GR, Kaibara T, Louw D, Hoult DI, Tomanek B, Saunders J. A
mobile high-field magnetic resonance system for neurosurgery. J Neurosurg
1999; 91: 804-13.
[387] Truwit CL, Hall WA. Intraoperative MR systems. High-field approaches.
Neuroimaging Clin N Am 2001; 11: 645-50.
[388] Liu H, Hall WA, Truwit CL. The roles of functional MRI in MR-guided
neurosurgery in a combined 1.5 Tesla MR-operating room. Acta Neurochir
Suppl 2003; 85: 127-35.
[389] Cannestra AF, Black KL, Martin NA, et al. Topographical and temporal
specificity of human intraoperative optical intrinsic signals. Neuroreport
1998; 9: 2557-63.
[390] Cannestra AF, Bookheimer SY, Pouratian N, et al. Temporal and
topographical characterization of language cortices using intraoperative
optical intrinsic signals. Neuroimage 2000; 12: 41-54.
[391] Cannestra AF, Pouratian N, Bookheimer SY, Martin NA, Beckerand DP,
Toga AW. Temporal spatial differences observed by functional MRI and
human intraoperative optical imaging. Cereb Cortex 2001; 11: 773-82.
[392] Haglund MM, Ojemann Ga, Hochman DW. Optical imaging of epileptiform
and functional activity in human cerebral cortex. Nature 1992; 358: 668-71.
[393] Haglund MM. Intraoperative optical imaging of epileptiform and functional
activity. Neurosurg Clin N Am 1997; 8: 413-20.
[394] Pouratian N, Bookheimer SY, O’Farrell AM, et al. Optical imaging of
bilingual cortical representations. J Neurosurg 2000; 93: 676-81.
[395] Pouratian N, Sheth S, Bookheimer SY, Martin NA, Toga AW. Applications
and limitations of perfusion-dependent functional brain mapping for
neurosurgical guidance. Neurosurg Focus 2003; 15: E2.
[396] Pouratian N, Sheth S, Martin NA, Toga AW. Shedding light on brain
mapping: advances in human optical imaging.Trends Neurosci. 2003; 26:
277-82.
[397] Sato K, Nariai T, Sasaki S, et al. Intraoperative intrinsic optical imaging of
neuronal activity from subdivisions of the human primary somatosensory
cortex. Cereb Cortex 2002; 12: 269-80
68 Hugues Duffau
[398] Schwartz TH, Chen LM, Friedman RM, Spencer DD, Roe AW.
Intraoperative optical imaging of human face cortical topography: a case
study. Neuroreport 2004; 15: 1527-31.
[399] Haglund MM, Berger MS, Hochman DW. Enhanced optical imaging of
human gliomas and tumor margins. Neurosurgery 1996; 38: 308-17.
[400] Kabuto M, Kabuto T, Kobayashi H, et al. Experimental and clinical study of
detection of glioma at surgery using fluorescent imaging by a surgical
microscope after fluorescein administration. Neurol Res 1997; 19: 9-16.
[401] Kuroiwa T, Kajimoto Y, Ohta T. Comparison between operative findings on
malignant glioma by a fluorescein surgical microscopy and histological
findings. Neurol Res 1999; 21: 130-4.
[402] Lin WC, Toms SA, Johnson M, Jansen ED, Mahadevan-Jansen A. In vivo
brain tumor demarcation using optical spectroscopy. Photochem Photobiol
2001; 73: 396-402.
[403] Sakatani K, Kashiwasake-Jibu M, Terada H, Zuo H. Development of
surgical confocal scanning microscope for intraoperative imaging of brain
tumors using near infrared fluorescence: technical note. Neurol Res 2000;
22: 533-6.
[404] Shinoda J, Yano H, Yoshimura SI, et al. Fluorescence-guided resection of
glioblastoma multiforme by using high-dose fluorescein sodium. J
Neurosurg 2003; 99: 597-603.
[405] Stummer W, Steep H, Möller G, Ehrhardt A, Leonhard M, Reulen HJ.
Technical principles for protoporphyrin-IX-fluorescence guided
microsurgical resection of malignant glioma tissue. Acta Neurochir (Wien)
1998; 140: 995-1000.
[406] Stummer W, Novotny A, Stepp H, Goetz C, Bise A, Reulen HJ.
Fluorescence-guided resection of glioblastoma multiforme by using 5-
aminolevulinic acid-induced porphyrins: a prospective study in 52
consecutive patients. J Neurosurg 2000; 93: 1003-13.
[407] Stummer W, Reulen HJ, Novotny A, Stepp H, Tonn JC. Fluorescence-
guided resections of malignant gliomas: an overview. Acta Neurochir Suppl
2003; 88: 9-12.
[408] Agari S, Rohrborn HJ, Engelhorn T, Stolke D. Intraoperative
characterization of gliomas by near-infrared spectroscopy: possible
association with prognosis. Acta Neurochir (Wien) 2003; 145: 453-9.
[409] Raabe A, Beck J, Gerlach R, Zimmermann M, Seifert V. Near-infrared
indocyanine green video angiography: a new method for intraoeprative
assessment of vascular flow. Neurosurgery 2003; 52: 132-9.
References 69
[410] Bakken HE, Kawasaki H, Oya H, Greenlee JDW, Howard MA. A device
for cooling localized regions of human cerebral cortex. J Neurosurg 2003;
99: 604-8.
[411] Lee GP, Loring DW, Smith JR, Flanigin HF. Intraoperative hippocampal
cooling and Wada memory testing in the evaluation of amnesia risk
following anterior temporal lobectomy. Arch Neurol 1995; 52: 857-61.
[412] Lee GP, Smith JR, Loring DW, Flanigin HF. Intraoperative thermal
inactivation of the hippocampus in an effort to prevent global amnesia after
temporal lobectomy. Epilepsia 1995; 36: 892-8.
[413] Keles GE, Berger MS. Advances in neurosurgical technique in the current
management of brain tumors. Semin Oncol 2004; 31: 659-65.
[414] Allison T, McArthy G, Wood CC, Darcey TM, Spencer DD, Williamson
PD. Human cortical potentials evoked by stimulation of the median nerve. I.
Cytoarchitectonic areas generating short latency activity. J Neurosurg 1989;
62: 694-710.
[415] Babu KS, Chandy MJ: Reliability of somatosensory evoked potentials in
intraoperative localization of the central sulcus in patients with perirolandic
mass lesions. Br J Neurosurg 1997; 11: 411-417.
[416] Cedzich C, Taniguchi M, Schäfer S, Schramm J. Somatosensory evoked
potential phase reversal and direct motor cortex stimulation during surgery
in and around the central region. Technical application. Neurosurgery 1996;
38: 962-971.
[417] Grant GA, Farrell D, Silbergeld DL. Continuous somatosensory evoked
potential monitoring during brain tumor resection. Report of four cases and
review of the literature. J Neurosurg 2002; 97: 709-13.
[418] Helmers SL. Evoked potentials for cortical mapping in children and adults,
in Loftus CM, Batjer HH, eds: Techniques in Neurosurgery. Philadelphia:
Lippincott Williams & Wilkins, 2001, Vol 7, pp 4-11.
[419] McCarthy G, Allison T, Spencer DD: Localization of the face area of
human sensorimotor cortex by intracranial recording of somatosensory
evoked potentials. J Neurosurg 1993; 79: 874-84.
[420] Mine S, Oka N, Yamaura, Nakajima Y. Presurgical functional localization
of primary somatosensory cortex by dipole tracing method of scalp-skull-
brain head model applied to somatosensory evoked potential.
Electroencephalogr Clin Neurophysiol 1998; 108: 226-33.
[421] Romstöck J, Fahlbusch R, Ganslandt O, Nimsky C, Strauss C. Localisation
of the sensorimotor cortex during surgery for brain tumours: feasibility and
waveform patterns of somatosensory evoked potentials. J Neurol Neurosurg
Psychiatry 2002; 72: 221-9.
70 Hugues Duffau
[422] Wood CC, Spencer DD, Allison D, McCarthy G, Williamson PD, Goff WR.
Localization of human sensorimotor cortex during surgery by cortical
surface recording of somatosensory evoked potentials. J Neurosurg 1988;
68: 99-111.
[423] King RB, Schell GR: Cortical localization and monitoring during cerebral
operations. J Neurosurg 1987; 67: 210-9.
[424] Wiedemayer H, Sandalcioglu IE, Armbruster W, Regel J, Schafer H, Stolke
D. False negative findings in intraoperative SEP monitoring: analysis of 658
consecutive neurosurgical cases and review of published reports. J Neurol
Neurosurg Psychiatry 2004; 75: 280-6.
[425] Neuloh G, Schramm J. Motor evoked potential monitoring for the surgery
of brain tumours and vascular malformations. Adv Tech Stand Neurosurg
2004; 29:171-228.
[426] Neuloh G, Pechstein U, Cedzich C, Schramm J. Motor evoked potential
monitoring with supratentorial surgery. Neurosurgery 2004; 54: 1061-70.
[427] Sala F, Lanteri P. Brain surgery in motor areas: the invaluable assistance of
intraoperative neurophysiological monitoring. J Neurosurg Sci 2003; 47:
79-88.
[428] Taniguchi M, Cedzich C, Schramm J. Modification of cortical stimulation
for motor evoked potentials under general anesthesia: technical description.
Neurosurgery 1993; 32: 219-26.
[429] Kombos T, Suess O, Ciklatekerlio O, Brock M. Monitoring of
intraoperative motor evoked potentials to increase the safety of surgery in
and around the motor cortex. J Neurosurg 2001; 95: 608-14.
[430] Kombos T, Suess O, Funk T, Kern BC, Brock M. Intraoperative mapping of
the motor cortex during surgery in and around the motor cortex. Acta
Neurochir 2000; 142: 263-8.
[431] Zentner J, Hufnagel A, Pechstein U, Wolf HK, Schramm J. Functional
results after resective procedures involving the supplementary motor area. J
Neurosurg 1996; 85: 542-549.
[432] Ikeda A, Miyamoto S, Shibasaki H. Cortical motor mapping in epilepsy
patients: information from subdural electrodes in presurgical evaluation.
Epilepsia 2002; 43 Suppl 9: S56-60.
[433] Lesser RP, Lüders H, Klem G, et al. Extraoperative cortical functional
localization in patients with epilepsy. J Clin Neurophysiol 1987; 4: 27-53.
[434] Lesser RP, Arroyo S, Crone N, Gordon B. Motor and sensory mapping of
the frontal and occipital lobes. Epilepsia 1998; 39 Suppl 4: S69-80.
References 71
[435] Lüders H, Lesser RP, Dinner DS, Morris HH, Wyllie E, Godoy J.
Localization of cortical function: new information from extraoperative
monitoring of patients with epilepsy. Epilepsia 1988; 29 Suppl 2: S56-65.
[436] Nii Y, Uematsu S, Lesser RP, Gordon B. Does the central sulcus divide
motor and sensory functions? Cortical mapping of human hand areas as
revealed by electrical stimulation through subdural grid electrodes.
Neurology 1996; 46: 360-7.
[437] Schlaffer L, Lüders HO, Beck GJ. Quantitative comparison of language
deficits produced by extraoperative electrical stimulation of Broca’s,
Wernicke’s, and basal temporal language areas. Epilepsia 1996; 37: 463-75.
[438] Uematsu S, Lesser R, Fisher RS, et al. Motor and sensory cortex in humans:
topography studied with chronic subdural stimulation. Neurosurgery 1992;
31: 59-71.
[439] Urasaki E, Uematsu S, Gordon B, Lesser RP. Cortical tongue area studied
by chronically implanted subdural electrodes--with special reference to
parietal motor and frontal sensory responses. Brain 1994; 117: 117-32.
[440] Chitoku S, Otsubo H, Harada Y, et al. Extraoperative cortical stimulation of
motor function in children. Pediatr Neurol 2001; 24: 344-50.
[441] Adelson PD, Black PM, Madsen JR, et al. Use of subdural grids and strip
electrodes to identify a seizure focus in children. Pediatr Neurosurg 1995;
22: 174-80.
[442] Cohen-Gadol AA, Britton JW, Collignon FP, Bates LM, Cascino GD,
Meyer FB. Nonlesional central lobule seizures: use of awake cortical
mapping and subdural grid monitoring for resection of seizure focus. J
Neurosurg 2003; 98: 1255-62.
[443] Lesser RP. Remission of intractable partial epilepsy following implantation
of intracranial electrodes. Neurology 2002; 58: 1317.
[444] Krone NE, Miglioretti DL, Gordon B, et al. Functional mapping of human
sensorimotor cortex with electrocorticographic spectral analysis. I. Alpha
and beta event-related desynchronization. Brai. 1998; 121: 2271-99.
[445] Krone NE, Miglioretti DL, Gordon B, Lesser RP. Functional mapping of
human sensorimotor cortex with electrocorticographic spectral analysis. II.
Event-related synchronization in the gamma band. Brain 1998; 121: 2301-
15.
[446] Krone NE. Functional mapping with ECoG spectral analysis. Adv Neurol
2000; 84: 343-51.
[447] Kirsch HE, Sepkuty JP, Crone NE. Multimodal functional mapping of
sensorimotor cortex prior to resection of an epileptogenic perirolandic
lesion. Epilepsy Behav 2004; 5: 407-10.
72 Hugues Duffau
[461] Lumenta CB, Gumprecht HK, Leonardi MA, Gerstner W, Brehm B. Three-
dimensional computer-assisted stereotactic-guided microneurosurgery
combined with cortical mapping of the motor area by direct
electrostimulation. Minim Invasive Neurosurg 1997; 40: 50-4.
[462] Manninen PH, Tan TK. Postoperative nausea and vomiting after craniotomy
for tumor surgery: a comparison between awake craniotomy and general
anesthesia. J Clin Anesth 2002;14:279-83.
[463] Meyer FB, Bates LM, Goerss BS, et al. Awake craniotomy for aggressive
resection of primary gliomas located in eloquent brain. Mayo Clin Proc
2001; 76: 677-87.
[464] Nikas DC, Danks RA, Black PM. Tumor surgery under local anesthesia, in
Loftus CM, Batjer HH, eds: Techniques in Neurosurgery. Philadelphia:
Lippincott Williams & Wilkins, 2001, Vol 7, pp 70-84.
[465] Peraud A, Meschede M, Eisner W, Ilmberger J, Reulen HJ. Surgical
resection of grade II astrocytomas in the superior frontal gyrus.
Neurosurgery 2002; 50: 966-77.
[466] Peraud A, Ilmberger J, Reulen HJ. Surgical resection of gliomas WHO
grade II and III located in the opercular region. Acta Neurochir (Wien)
2004; 146: 9-17.
[467] Reithmeier T, Krammer M, Gumprecht H, Gerstner W, Lumenta CB.
Neuronavigation combined with electrophysiological monitoring for
surgery of lesions in eloquent brain areas in 42 cases: a retrospective
comparison of the neurological outcome and the quality of resection with a
control group with similar lesions. Minim Invasive Neurosurg 2003; 46: 65-
71.
[468] Reulen HJ, Schmid UD, Ilmberger J, Eisner W, Bise K. Tumor surgery of
the speech cortex in local anesthesia. Neuropsychological and
neurophysiological monitoring during operations in the dominant
hemisphere. Nervenarzt 1997; 68: 813-24.
[469] Sarang A, Dinsmore J. Anesthesia for awake craniotomy – evolution of a
technique that facilitates awake neurological testing. Br J Anaesth
2003;90:161-5.
[470] Signorelli F, Guyotat J, Isnard J, Schneider F, Mohammedi R, Bret P. The
value of cortical stimulations applied to the surgery of malignant gliomas in
language areas. Neurol Sci 2001; 22: 3-10.
[471] Signorelli F, Guyotat J, Mottolese C, Schneider F, D'Acunzi G, Isnard J.
Intraoperative electrical stimulation mapping as an aid for surgery of
intracranial lesions involving motor areas in children. Childs Nerv Syst
2004; 20: 420-6.
74 Hugues Duffau
[510] Schulder M, Maldjian LA, Liu WC, et al. Functional image-guided surgery
of intracranial tumors located near the sensorimotor cortex. J Neurosurg
1998; 89: 412-418.
[511] Signorelli F, Guyotat J, Schneider F, Isnard J, Bret P. Technical refinements
for validating functional MRI-based neuronavigation data by electrical
stimulation during cortical language mapping. Minim Invasive Neurosurg
2003; 46: 265-8.
[512] Yousry TA, Schmid UD, Jassoy AG, et al. Topography of the cortical motor
hand area: prospective study with functional MR imaging and direct motor
mapping at surgery. Radiology 1995; 195: 23-9.
[513] Castillo EM, Simos PG, Wheless JW, et al. Integrating sensory and motor
mapping in a comprehensive MEG protocol: clinical validity and
replicability. Neuroimage. 2004; 21: 973-83.
[514] Morioka T, Mizushima A, Yamamoto T, et al. Functional mapping of the
sensorimotor cortex: combined use of magnetoencephalography, functional
MRI, and motor evoked potentials. Neuroradiology 1995; 37: 526-30.
[515] Ishibashi H, Morioka T, Nishio S, Shigeto H, Yamamoto T, Fukui M.
Magnetoencephalographic investigation of somatosensory homunculus in
patients with peri-Rolandic tumors. Neurol Res 2001; 23: 29-38.
[516] Roberts TP, Zusman E, Mcdermott M, Barbaro N, Rowley HA. Correlation
of functional magnetic source imaging with intraoperative cortical
stimulation in neurosurgical patients. J Image Guid Surg 1995; 1: 339-47.
[517] Roberts TP, Ferrari P, Perry D, Rowley HA, Berger MS. Presurgical
mapping with magnetic source imaging: comparisons with intraoperative
findings. Brain Tumor Pathol 2000; 17: 57-64.
[518] Schiffbauer H, Berger MS, Ferrari P, Freudenstein D, Rowley HA, Roberts
TP. Preoperative magnetic source imaging for brain tumor surgery: a
quantitative comparison with intraoperative sensory and motor mapping.
Neurosurg Focus 2003;15:E7.
[519] Simos PG, Breier JI, Maggio WW, et al. Atypical temporal lobe language
representation: MEG and intraoperative stimulation mapping correlation.
Neuroreport 1999; 10: 139-42.
[520] Yetkin FZ, Mueller WM, Morris GL, et al. Functional MR activation
correlated with intraoperative cortical mapping. AJNR 1997; 18: 1311-5.
[521] Roux FE, Ibarrola D, Tremoulet M, et al. Methodological and technical
issues for integrating functional magnetic resonance imaging data in a
neuronavigational system. Neurosurgery 2001; 49: 1145-57.
[522] Lehéricy S, Duffau H, Cornu P, et al. Correspondence between functional
magnetic resonance imaging somatotopy and individual brain anatomy of
78 Hugues Duffau
capacity, 1
B capsule, 15, 17, 18, 74
carbon, 43
basal ganglia, 74
carcinoma, 49
behavior, v, 3, 7
case study, 68
beta, 71
causal model, 84
bilateral, 11, 27
CBF, 10
bilingual, 67, 82
cell, 7, 41, 45
biochemical, 6, 47
cells, 7, 11
biological, v, 1, 3, 7, 33, 34, 39
central nervous system, 1, 3, 9, 33, 37, 43, 72
biological behavior, 1, 3, 7, 33
central nervous system (CNS), 1, 3, 9, 33, 37,
biological models, 34
43, 52, 72
biology, 4
cerebral blood flow, 10
biophysical, 53
cerebral blood volume (CBV), 7, 48, 53
biopsies, 5, 6, 41, 44, 45, 66
cerebral function, 35
biopsy, 4, 6, 15, 42, 43, 47, 66
cerebral hemisphere, 39, 82, 83, 84
blood, 7, 10, 11, 12, 16, 41, 48, 49, 53, 54, 55,
cerebral mapping, 4
60, 78
cerebrospinal fluid (CSF), 12, 14
blood flow, 10, 12, 16
chemical, 48
blood oxygenation level-dependent, 11, 53, 78
chemotherapy, 4, 5, 35, 41, 43
blood-brain barrier (BBB), 41
children, 17, 61, 69, 71, 72, 73
BOLD, 11, 12, 34, 53, 54, 55, 57, 84
chloride, 41
brachytherapy, 44
chromosome, 40
brain, v, vii, viii, 1, 3, 4, 5, 6, 7, 9, 10, 11, 12,
chronic, 31, 71
13, 14, 15, 16, 20, 21, 23, 24, 25, 27, 28,
chronically, 71
29, 31, 33, 34, 35, 37, 38, 39, 40, 41, 42,
classical, 1, 4, 17, 25, 26
43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53,
classification, 7, 40, 45, 78
54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64,
clinical, vii, 4, 5, 9, 10, 12, 20, 26, 39, 40, 46,
65, 66, 67, 68, 69, 70, 72, 73, 74, 76, 77,
49, 51, 52, 63, 68, 77, 79, 80
78, 79, 80, 81, 82, 83, 84
cluster of differentiation (CD), 55
brain abscess, 48
Co, 76
brain activity, 52, 56
cognition, 74
brain functions, 50
cognitive, 18, 24, 28
brain injury, 50
cognitive function, 18, 24, 28
brain tumor, vii, viii, 1, 3, 4, 5, 6, 7, 11, 12,
coil, 12
13, 23, 27, 31, 34, 35, 40, 41, 42, 44, 45,
communication, 57
46, 47, 48, 49, 52, 53, 54, 55, 56, 57, 59,
compensation, viii, 4, 10, 15, 19, 23, 25, 27,
60, 62, 64, 65, 66, 68, 69, 72, 76, 77, 78
28, 29, 33, 37, 64, 65, 81
brainstem, 43
complementary, 4, 7, 35
complications, 15, 18, 66, 82
C compounds, 5, 46
comprehension, 18, 76, 81
cancer, 40 computed tomography, 39, 42
Cancer, 38, 39, 40, 42, 43, 44, 46, 79, 82, 83 computer, 73
cancers, 37 concentration, 11, 53, 54
Index 87
conception, 1, 9 dendritic cell (DC), 37, 38, 43, 51, 63, 73, 82
concordance, 21 density, 5, 7
conformational, 35 deoxyhemoglobin, 12, 54
Congress, iv detection, 19, 41, 42, 43, 55, 63, 68
connectivity, vii, viii, 14, 18, 31, 33, 34, 60, deviation, 59, 81
72, 75, 84 diagnosis, 4, 42, 44, 46
consumption, 11 diagnostic, 4, 43, 47, 65
contralateral, 25, 78 differential diagnosis, 4, 41, 44
contralateral hemisphere, 78 differentiation, 46
contrast agent, 42 diffusion, 7, 13, 15, 34, 48, 49, 58, 59, 60, 62
control, 15, 19, 29, 49, 73, 78, 82 diffusion tensor imaging (DTI), 13, 14, 59, 60
control group, 73 diffusion-weighted imaging (DWI), 7, 13, 48
controlled, 17 diffusivity, 7, 13
cooling, 16, 69 digital images, 15
corona, 17, 18 dipole, 69
corpus callosum, 3, 28, 81 discrimination, 6, 46, 48
correlation, 12, 44, 45, 48, 54, 55, 57, 62, 76, disorder, 80
77, 80 displacement, 14, 15, 51, 63
correlations, 9, 18, 20 dissociation, 81
cortex, 10, 12, 16, 18, 19, 25, 27, 37, 50, 51, distribution, 5, 16
52, 53, 54, 55, 56, 57, 60, 62, 67, 69, 70, DNA, 40
71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 83 dominance, 54, 58
cortical, vii, 9, 10, 15, 16, 17, 18, 19, 20, 24, dorsolateral prefrontal cortex, 19
32, 37, 50, 51, 52, 53, 54, 56, 57, 60, 61, DSC, 49
63, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, dyslexia, 79
77, 79, 81, 82
corticospinal, 60, 62
coupling, 11, 26, 34, 47, 54, 84 E
craniotomy, 13, 20, 63, 72, 73, 74, 83
E6, 61
CT, 14, 38
E7, 77
CT scan, 38
EEG, 10, 34
current limit, 16
efficacy, 10, 15, 40, 67
electric current, 12
D electrical, vii, viii, 12, 13, 16, 18, 20, 21, 27,
29, 31, 34, 50, 54, 55, 56, 57, 71, 72, 73,
data set, 47 75, 77, 79, 81, 82, 84
death, 50 electrodes, 18, 70, 71
decision making, 12, 15, 57, 66 electroencephalography, 12
decompression, 15 electromagnetic, 12
deficit, vii, viii, 1, 11, 13, 20, 23, 26, 29, 32, electronic, iv
78, 80 electrophysiological, 15, 16, 17, 18, 33, 73,
deficits, 17, 71, 80, 84 76, 78
deformation, 20, 63, 64 electrophysiology, 34, 74, 78
degree, 4 electrostatic, iv
delta, 12, 56 emission, 10, 41, 42, 43, 44
88 Index
emitters, 4
energy, 6, 45, 54
G
environment, 62, 64
ganglia, 74
epilepsy, 17, 70, 71, 72, 79, 80
gene, 4, 41
event-related desynchronization, 71
gene expression, 4
evidence, 11, 79, 80
gene therapy, 4
evoked potential, 16, 17, 18, 57, 69, 70, 72,
general anesthesia, 18, 70, 73
77, 83
generation, 76
evolution, 3, 35, 54, 73, 80
genetics, 37
examinations, 35
Germany, 49
excision, 72, 83
glatiramer acetate (GA), 69, 72, 74, 75, 80,
excitability, 24
81, 82
expert, iv
glial, 39, 45, 48, 80
extracranial, 12
glioblastoma, 43, 49, 54, 68, 83
eye, 29, 81
glioblastoma multiforme, 49, 54, 68, 83
eye movement, 81
glioma, 3, 4, 6, 11, 15, 16, 19, 24, 25, 27, 28,
eye movements, 81
29, 33, 35, 38, 39, 40, 41, 42, 43, 44, 45,
46, 47, 49, 51, 52, 68, 74, 75, 78, 81, 82, 83
F gliomas, 3, 4, 5, 6, 7, 10, 14, 15, 17, 23, 25,
26, 27, 28, 38, 40, 41, 42, 43, 44, 46, 47,
facial palsy, 28 48, 49, 52, 54, 59, 60, 66, 68, 72, 73, 74,
factor i, 43, 44, 83 75, 78, 79, 82, 83, 84
false, 12, 54 gliosis, 6
family, 26, 35 glucose, 5, 16, 43
FDG, 5, 34, 42, 43, 44, 51 glucose metabolism, 16
fiber, 14, 58, 59, 60 goals, vii
fibers, 13, 14, 16, 17, 60 gold, 16
flow, 68 grading, 7, 42, 44, 46, 49
fluid, 12, 14 gravity, 14
fluorescence, 68 gray matter, 12
fluorine, 43 grey matter, 13, 50
fMRI, vii, 10, 11, 12, 14, 20, 25, 26, 27, 34, grids, vii, 17, 18, 71
52, 53, 56, 57, 61, 76, 78 groups, 17
follow-up, 34, 42, 65 growth, 1, 3, 4, 10, 29, 33, 35, 38, 40, 78
fractional anisotropy, 13, 59 guidance, 5, 12, 29, 61, 63, 64, 65, 66, 67
frontal lobe, 53, 79, 80 gyrus, 24, 27, 29, 73, 82
functional architecture, 48
functional aspects, 80
functional imaging, 37, 57, 75
H
functional magnetic resonance imaging
head, 14, 24, 28, 56, 57, 69
(MRI), 10, 15, 51, 52, 53, 54, 57, 58, 61,
head injury, 24
62, 67, 76, 77, 78, 81
hemiparesis, 78
fusion, 64
hemiplegia, 15, 49, 79
Index 89
hemisphere, 3, 12, 13, 24, 26, 27, 28, 73, 78, inflammation, 6
79, 80, 82, 83 infrared, 68
hemodynamic, 34 injection, 15, 44
hemodynamics, 54, 84 injury, iv, 1, 24, 50
hemoglobin, 11, 12, 53 inositol, 46
herpes, 42 integration, 6, 14, 15, 31, 61, 62, 76, 84
herpes simplex, 42 integrity, 13
herpes simplex virus type 1, 42 intensity, 48
heterogeneity, 4 interaction, 35
heterogeneous, 5 interactions, v, vii, viii, 1, 2, 4, 23, 33, 35
high grade glioma, 3, 6, 7 interface, 26, 34
high risk, 14, 27 interleukin (IL), 37
hippocampal, 69 International Agency for Research on Cancer,
hippocampus, 69 37
histological, 3, 14, 48, 68 interpretation, 17, 34, 54, 64, 84
histology, 5, 44 interstitial, 7, 64
histopathology, 46, 47 intracerebral, 52, 54, 55, 81
homogeneity, 34 intracranial, 41, 49, 65, 69, 71, 73, 77, 83
host, vii, 1, 35 intracranial tumors, 77
human, 10, 37, 40, 44, 45, 46, 48, 50, 55, 59, intraoperative, vii, 13, 14, 15, 16, 17, 18, 20,
60, 67, 68, 69, 70, 71, 72, 78, 79, 81 21, 24, 27, 28, 29, 31, 33, 34, 50, 51, 52,
human brain, 45, 46, 48, 50, 55, 59, 60 53, 55, 60, 61, 62, 63, 64, 65, 66, 67, 68,
human cerebral cortex, 37, 67, 69 69, 70, 72, 74, 75, 76, 77, 78, 79, 80, 81, 82
humans, 9, 50, 55, 60, 71, 79, 80 intravenous (IV), 23
hybrid, 47 intrinsic, 15, 24, 55, 67, 72, 81
hypothesis, 9, 37, 80 invasive, vii, 16, 20, 31, 44, 45, 60, 64, 66, 72,
76, 78
iodine, 42
I ipsilateral, 24, 56
irradiation, 62
identification, 6, 13, 16, 17, 21, 52, 53, 61, 72,
74, 76
images, 6, 11, 14, 44, 47, 60 J
imaging, vii, 4, 7, 10, 12, 13, 14, 15, 20, 21,
23, 25, 37, 40, 41, 42, 45, 46, 47, 48, 49, JI, 56, 58, 60, 77
51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, JT, 76
62, 63, 64, 65, 66, 67, 68, 75, 76, 77
immunohistochemical, 6
implementation, 61, 64, 65 K
in vitro, 9, 46
KH, 48, 52, 57, 83
in vivo, 42, 44, 45, 46, 59, 63
Ki-67, 46
inactivation, 16, 69
King, 70
indication, viii, 23
induction, 12, 27
infectious, 18
inferior frontal gyrus, 19, 27
90 Index
magnetic, iv, 12, 43, 44, 45, 46, 47, 48, 49,
L 51, 52, 53, 55, 56, 57, 58, 59, 60, 62, 64,
65, 66, 67, 76, 77
labeling, 46
magnetic field, 12, 56
Langerhans cells (LC), 43
magnetic resonance, 43, 44, 45, 46, 47, 48, 49,
language, 10, 11, 12, 15, 17, 18, 19, 20, 24,
51, 52, 53, 55, 58, 59, 60, 62, 64, 65, 66,
26, 27, 28, 29, 35, 37, 51, 52, 53, 54, 56,
67, 76
58, 60, 61, 67, 71, 72, 73, 74, 75, 76, 77,
magnetic resonance image, 58, 60, 65
78, 81, 82
magnetic resonance imaging (MRI), 6, 7, 10,
latency, 17, 69
15, 19, 25, 26, 34, 35, 43, 47, 48, 49, 51,
laterality, 58
52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62,
lead, 13, 14, 19, 29
64, 65, 66, 67, 76, 77, 78, 81
leakage, 14
magnetic resonance spectroscopy (MRS), 5, 6,
learning, 1, 9, 37
34, 45, 46, 47
lesion, vii, viii, 1, 3, 5, 6, 9, 10, 12, 13, 16, 17,
magnetoencephalography, 10, 12, 52, 55, 57,
18, 24, 25, 27, 33, 54, 61, 71
58, 61, 62, 77, 79
lesions, 1, 5, 6, 7, 9, 14, 17, 23, 24, 26, 43, 44,
magnetometry, 58
45, 48, 49, 51, 52, 54, 55, 56, 57, 58, 60,
magnets, 15
61, 62, 63, 69, 72, 73, 74, 78, 79
malignant, 5, 38, 41, 43, 46, 47, 68, 73
limitation, 20, 23, 52
management, 5, 13, 38, 39, 43, 52, 69, 74, 82,
limitations, 17, 67
83, 84
linear, 59
manganese, 60
lipid, 46
mapping, vii, viii, 1, 4, 9, 10, 11, 12, 13, 14,
lipids, 6, 46
15, 16, 17, 18, 19, 20, 21, 24, 26, 29, 31,
literature, 4, 9, 32, 69
32, 33, 34, 49, 51, 52, 53, 55, 56, 57, 59,
lobectomy, 69
60, 61, 62, 67, 69, 70, 71, 72, 73, 74, 75,
local anesthesia, 18, 72, 73
76, 77, 78, 79, 80, 81, 82, 83
local anesthetic, 74
mask, 72
localization, 15, 16, 17, 51, 52, 53, 55, 56, 57,
mathematical, 15, 40
69, 70, 72, 74, 76
MDR, 41
location, vii, 10, 16, 17, 28, 51
mean, 3, 7, 13, 31, 38
long-distance, 18
measurement, 14, 48, 54, 63
longitudinal study, viii
measures, 13
long-term, viii, 1, 9, 29
mechanical, iv, 17
low-grade glioma, 1, 3, 5, 6, 7, 11, 28, 32, 37,
median, 3, 16, 69
38, 40, 43, 44, 45, 46, 66, 74, 75, 79, 80,
medulloblastomas, 7
81, 82, 83, 84
MEG, vii, 10, 12, 14, 20, 34, 56, 57, 62, 77
lymphoma, 7, 49
melanoma, 49
lymphomas, 7
memory, 1, 15, 17, 18, 69
MET, 5
M metabolic, 4, 5, 6, 11, 13, 15, 20, 31, 33, 43,
44, 62
magnet, 65, 66 metabolic changes, 5, 6
metabolism, 6, 7, 16, 34, 45, 47, 54, 84
metabolite, 6
Index 91
N observations, 9
occipital, 70
NAA, 5 occipital lobe, 70
naming, 18, 81 ocular, 81
92 Index
severity, 26 66, 68, 69, 70, 72, 73, 74, 75, 77, 79, 80,
short-term, vii, 50 82, 83, 84
sign, 17 surgical, vii, viii, 1, 3, 4, 10, 11, 13, 14, 15,
signals, 55, 67 18, 21, 23, 24, 25, 27, 29, 31, 32, 33, 34,
signs, 17 37, 52, 61, 64, 66, 68, 74, 75, 80, 81, 82
simulation, 13, 58 surgical resection, 11, 24, 29, 37, 75, 80, 81
simulations, 40 survival, 3, 4, 5, 6, 38, 39, 40, 41, 42, 44, 46,
sites, vii, 19, 20, 24, 28, 29, 50, 60, 74, 79 83
skin, 12 susceptibility, 49, 53
slow-growing glioma, 4 symptom, 4
SMA, 11, 25, 26 symptoms, 27
sodium, 68 synapses, 84
solution, 53 synaptic plasticity, 50
solutions, 42 synchronization, 18, 71
somatosensory, 16, 17, 18, 24, 29, 51, 56, 67, syndrome, 11, 25, 26, 27, 79, 80, 81, 82
69, 70, 76, 77, 79 synthetic, 58
somatosensory function, 18, 76 systematic, 28
spatial, 5, 6, 10, 13, 14, 15, 57, 61, 67 systems, 6, 67
spatial analysis, 57
specialists, 35
specificity, 11, 21, 34, 41, 67 T
SPECT, 4, 41, 42, 43
tactile, 52
spectra, 45, 46
technetium, 41
spectral analysis, 17, 71
technological, 66
spectroscopy, 5, 45, 46, 47, 48, 68
technology, 55, 63
speech, 18, 27, 37, 58, 73, 75, 80, 81, 83
temporal, 27, 29, 34, 55, 56, 58, 67, 69, 71,
spin, 58
74, 77, 79
statistical analysis, 39, 84
temporal lobe, 56, 69, 74, 77
strategies, 53, 59, 72, 83
Tesla, 66, 67
strength, 15, 65, 67
thallium, 41, 42
striatum, 28, 81
therapeutic, 35, 40
stroke, 1, 6, 10, 27, 37, 50, 51
therapy, 4, 5, 6, 7, 39, 40, 41, 47, 49, 65, 83,
subcortical structures, 9, 16, 28
84
subcutaneous (SC), 48, 60
thermal, 16, 69
subjective, 35
theta, 12
substitution, 10
three-dimensional (3D), 15, 20, 45, 47, 60, 62,
substrates, 5
63, 64, 76
subtraction, 81
thresholds, 20
Sun, 41, 64
time, 1, 2, 3, 4, 5, 15, 17, 20, 26, 29, 54, 80,
superconducting, 55
83
suppression, 81
time consuming, 15
surgeries, 32, 35
timing, 40
surgery, iii, vii, viii, 1, 2, 6, 10, 12, 13, 14, 15,
tissue, 7, 11, 15, 20, 46, 63, 68
16, 17, 18, 20, 21, 23, 26, 27, 29, 31, 32,
tissue perfusion, 7
33, 34, 35, 38, 39, 55, 56, 61, 62, 64, 65,
tissues, 59
Index 95
tolerance, 72
tracers, 4, 5
V
tracking, 13, 58, 59, 60
validation, 47, 56, 76, 78
tractography, 58, 62
validity, 77
training, 50
values, 7
transcranial magnetic stimulation, 57
variability, vii, 1, 29, 37, 79
transformation, 3, 4, 6, 10, 33
variables, 39
transgene, 42
vascular, 34, 51, 68, 70, 78
treatment, 3, 6, 12, 32, 35, 38, 42, 56, 62, 83
video, 16, 68
trial, 38, 74
virus, 42
tumo(u)r, v, vii, viii, 1, 3, 4, 5, 6, 7, 10, 11,
visible, 14
12, 13, 15, 16, 19, 20, 23, 27, 29, 31, 32,
vision, 3, 9
33, 34, 35, 38, 41, 42, 43, 46, 47, 48, 49,
visual, 10, 12, 18, 42, 52, 54, 56, 75
51, 52, 54, 55, 56, 59, 60, 62, 64, 66, 67,
visualization, 62
68, 69, 72, 73, 75, 77, 83
vomiting, 73
tumor cells, 6
tumor mapping, 4
tumor progression, 6, 83 W
tumor proliferation, 4
tumo(u)rs, vii, viii, 1, 3, 4, 5, 6, 7, 12, 14, 16, water, 7, 10, 13, 34, 52, 59
17, 18, 26, 31, 32, 34, 35, 37, 40, 41, 42, water diffusion, 13, 59
43, 44, 45, 46, 47, 48, 49, 51, 52, 53, 54, weakness, 52
56, 57, 59, 60, 63, 65, 66, 68, 69, 70, 72, white matter, 3, 13, 17, 18, 59, 60, 74, 75
74, 76, 77, 78, 80, 81, 82, 83, 84 World Health Organization (WHO), 3, 40, 49,
turnover, 5 73, 83, 84
tyrosine, 4, 5, 42, 44 writing, 18, 29
U X
ultrasonography, 63 xenograft, 49
ultrasound, 15, 63, 64
United States, 37
unmasking, 10, 24, 29, 50, 79 Y
updating, 64
yield, 43, 47, 66